Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Discussions on NHI Drug Pricing System Reform Remain Halted at Chuikyo
October 5, 2009
- PMS Activities Put Additional Burden on Doctors
October 5, 2009
- Price Gaps Remain Unchanged for Drugs Priced by Similar Efficacy Comparison Method
October 5, 2009
- Fixed-Dose Combination Drugs Should Be Priced at 10-30% of the Sum of Prices of Combined Drugs: Korosho
October 5, 2009
- Term of Office to Expire for 6 of 7 Chuikyo Members Representing Healthcare Providers
October 5, 2009
- Measures to Promote Development of Unapproved Drugs Proposed by Industry
October 5, 2009
- REGULATORY NEWS IN BRIEF
October 5, 2009
- SURVEY／60% of Doctors Voted for DPJ Because of Frustration with LDP
October 5, 2009
- Biomarker Science to Develop Alternative Therapy for Heart Transplantation
October 5, 2009
- JPMA to Disclose More Information on Clinical Studies
October 5, 2009
- Kenporen Records Second-Largest Deficit in FY2008
October 5, 2009
- JPMA Studies How to Support Bioventures
October 5, 2009
- BSP Aims at Growing Twice as Fast as Market in Japan
October 5, 2009
- R&D NEWS IN BRIEF
October 5, 2009
- Eisai, Pfizer to Continue Copromotion of Aricept
October 5, 2009
- Nihon Chouzai, Matsumotokiyoshi Give Up Business Alliance
October 5, 2009
- Quintiles to Start COPD Management Services
October 5, 2009
- Hoyu Acquires 4 Kracie Group Companies
October 5, 2009
- DSP Starts Shipping New Amlodin OD Tab Produced Using SUITAB-NEX Technology
October 5, 2009
- Patient Recognition Criteria Approved for 11 Designated Diseases
October 5, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…